

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

May 19, 2026

LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.

Detailed results of the vote follow:

Name	For	Withheld	Broker Non-Votes
Thomas J. Appio	196,814,621	2,743,810	79,859,605
Christian A. Garcia	196,711,908	2,846,523	79,859,605
Michael Goettler	196,757,828	2,800,603	79,859,605
Sarah B. Kavanagh	188,459,870	11,098,561	79,859,605
Frank D. Lee	183,885,617	15,672,814	79,859,605
Sandra Leung	195,931,772	3,626,659	79,859,605
John A. Paulson	196,214,806	3,343,625	79,859,605
Robert N. Power	186,236,066	13,322,365	79,859,605
Eiry W. Roberts, M.D.	196,972,752	2,585,679	79,859,605
Amy B. Wechsler, M.D.	195,813,955	3,744,476	79,859,605

Shareholders also approved, on a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as the Company's auditor until the close of the Company's 2027 Annual Meeting of Shareholders, and the authorization for the board of directors to fix the auditor's remuneration.

The final vote tabulation on all matters voted on at the Annual Meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at www.bauschhealth.com

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit

www.bauschhealth.com

and connect with us on

[LinkedIn](#).

Investor Contact:

Garen Sarafin

ir@bauschhealth.com

(877) 281-6642 (toll free)

Media Contact:

Katie Savastano

corporate.communications@bauschhealth.com

(908) 569-3692

BHC-AGM



View original content to download multimedia:

<https://www.prnewswire.com/news-releases/bausch-health-announces-2026-annual-meeting-of-shareholder-results-302776740.html>

SOURCE Bausch Health Companies Inc.



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION